Endpoints News
Facts
- Sectors
- Media, Biotech reporting
- Founded
- 2016
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
Gennev Founder Jill Angelo Steps Down After Acquisition; Aurion Biotech CEO Replaced Following Alcon Majority Stake; Temporal Adds New Leadership
Jill Angelo, founder and CEO of menopause startup Gennev, stepped down following its acquisition by Unified Women’s Healthcare, while Aurion Biotech replaced CEO Greg Kunst with Arnaud Lacoste after Alcon acquired a majority stake. Temporal also announced leadership additions with Jim Cyb as president and Sahir Azam as an independent board member.
Affini-T Therapeutics Closes Seattle Lab, Offering Some Employees Relocation to Boston
Affini-T Therapeutics, a cell therapy company specializing in T cell receptor cancer immunotherapy, is closing its Seattle lab, impacting 17 employees, some of whom may relocate to Boston. The company raised $175 million last year and was spun out of Fred Hutchinson Cancer Research Center.
By Endpoints News
BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
BrainChild Bio raised $116 million in a Series A to fund a pivotal trial of a B7-H3–targeted CAR-T therapy for pediatric diffuse intrinsic pontine glioma (DIPG), aiming to make CAR-Ts function more like small molecules for brain tumors.
